|
Oct 10
|
Tilray CEO Bullish on Cannabis Legalization Following 2024 Election
|
|
Oct 10
|
Tilray Brands (TLRY) Q1 2025 Earnings Call Transcript
|
|
Oct 10
|
Tilray Brands considers US brewery consolidation
|
|
Oct 10
|
Tilray Brands (TLRY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Oct 10
|
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Lags Revenue Estimates
|
|
Oct 10
|
Tilray Brands Reports Q1 2025 Financial Results
|
|
Jul 30
|
What the US can gain from rescheduling marijuana: Tilray CEO
|
|
Jul 30
|
Why Tilray’s big beverage bet is paying off: CEO
|
|
Jul 30
|
Tilray, Diageo, SoFi: Why these tickers are trending
|
|
Jul 30
|
Tilray Brands (TLRY) Q4 2024 Earnings Call Transcript
|
|
Jul 29
|
Tilray Brands (TLRY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Jul 29
|
Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Tops Revenue Estimates
|
|
Jul 29
|
Tilray, F5, Lattice Semi: After-hours movers
|
|
Jul 29
|
Tilray Up 9.8% After Hours As Posts a Narrower Fiscal Q4 Loss as it Beats a Revenue Forecast
|
|
Jul 29
|
Tilray Brands Reports Record Financial Results, Achieves 26% Net Revenue Growth
|
|
Jul 29
|
Tilray Up in US Pre-Market As Subsidiary Secures Cannabis Trading License in Germany
|
|
Jul 29
|
Tilray’s Aphria RX Receives Cannabis Trading License in Germany, Significantly Expanding Commercial Growth Opportunities
|
|
Jul 24
|
Tilray Brands (TLRY) Lined Up for Q4 Earnings: What Awaits?
|
|
Jul 24
|
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
|
|
Jul 23
|
Tilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights
|